Exosomal micrornas derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection

Stem Cells Translational Medicine

Volumn 5, Issue 9, 2016, Pages 1190-1203

  Qian, Xijing ^a   Xu, Chen ^a   Fang, Shuo ^a   Zhao, Ping ^a   Wang, Yue ^a   Liu, Houqi ^a   Yuan, Wen ^a   Qi, Zhongtian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral therapy; Exosomes; Hepatitis C virus; MicroRNA; Umbilical mesenchymal stem cell

Indexed keywords

5' NUCLEOTIDASE; ALPHA INTERFERON; ANTAGOMIR; ARGONAUTE 2 PROTEIN; BETA INTERFERON; BETA1 INTEGRIN; CD63 ANTIGEN; CD81 ANTIGEN; DASATINIB; ENDOGLIN; GAMMA INTERFERON; HERMES ANTIGEN; MICRORNA; MICRORNA 125B; MICRORNA 1260A; MICRORNA 1260B; MICRORNA 145; MICRORNA 199A; MICRORNA 221; MICRORNA 222; MICRORNA LET 7F; RETINOIC ACID INDUCIBLE PROTEIN I; TELAPREVIR; THY 1 ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CELL ISOLATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; EXOSOME; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MESENCHYMAL STEM CELL TRANSPLANTATION; PARACRINE SIGNALING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA IMMUNOPRECIPITATION ASSAY; RNA ISOLATION; VIRUS REPLICATION; WESTERN BLOTTING; CELL CULTURE; CYTOLOGY; FETUS BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HEPACIVIRUS; MESENCHYMAL STROMA CELL; METABOLISM; POLYMERASE CHAIN REACTION;

ANTIVIRAL AGENTS; CELLS, CULTURED; EXOSOMES; FETAL BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOPRECIPITATION; MESENCHYMAL STROMAL CELLS; MICRORNAS; POLYMERASE CHAIN REACTION;

EID: 84983421363     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0348     Document Type: Article

References (61)

1. Ippolito G, Capobianchi MR, Lanini S et al. Is hepatitis C virus eradication around the corner only 25 years after its discovery? Int J Antimicrob Agents 2015;45:111–112.
2. Cox AL. MEDICINE. Global control of hepatitis C virus. Science 2015;349:790–791.
3. Kohli A, Shaffer A, Sherman A et al. Treatment of hepatitis C: A systematic review. JAMA 2014;312:631–640.
4. Petta S, Craxì A. Current and future HCV therapy: Do we still need other anti-HCV drugs? Liver Int 2015;35(suppl 1):4–10.
5. Kode JA, Mukherjee S, Joglekar MV et al. Mesenchymal stem cells: Immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009;11:377–391.
6. Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol 2012;3:359.
7. D’souza N, Rossignoli F, Golinelli G et al. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. BMC Med 2015;13:186.
8. Zaher W, Harkness L, Jafari A et al. An update of human mesenchymal stem cell biology and their clinical uses. Arch Toxicol 2014;88: 1069–1082.
9. Tan X, Gong YZ, Wu P et al. Mesenchymal stem cell-derived microparticles: A promising therapeutic strategy. Int J Mol Sci 2014;15: 14348–14363.
10. Caplan AI. MSCs: The sentinel and safe-guards of injury. J Cell Physiol 2016;231: 1413–1416.
11. Liang X, Ding Y, Zhang Y et al. Paracrine mechanisms of mesenchymal stem cell-based therapy: Current status and perspectives. Cell Transplant 2014;23:1045–1059.
12. Konala VB, Mamidi MK, Bhonde R et al. The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration. Cytotherapy 2016;18: 13–24.
13. Chen W, Liu J, Manuchehrabadi N et al. Umbilical cord and bone marrow mesenchymal stem cell seeding on macroporous calcium phosphate for bone regeneration in rat cranial defects. Biomaterials 2013;34: 9917–9925.
14. Van Pham P, Truong NC, Le PT et al. Isolation and proliferation of umbilical cord tissue derived mesenchymal stemcellsforclinical applications. Cell Tissue Bank 2015 Dec 17 [E-pub ahead of print].
15. Jung Y, Bauer G, Nolta JA. Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: Progress toward safe clinical products. STEM CELLS 2012;30:42–47.
16. Biancone L, Bruno S, Deregibus MC et al. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant 2012;27:3037–3042.
17. Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci 2014;15:4142–4157.
18. Bobrie A, Colombo M, Raposo G et al. Exosome secretion: Molecular mechanisms and roles in immune responses. Traffic 2011; 12:1659–1668.
19. O’Loughlin AJ, Woffindale CA, Wood MJ. Exosomes and the emerging field of exosomebased gene therapy. Curr Gene Ther 2012;12: 262–274.
20. Valadi H, Ekström K, Bossios A et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9:654–659.
21. Mathivanan S, Fahner CJ, Reid GE et al. ExoCarta 2012: Database of exosomal proteins, RNA and lipids. Nucleic Acids Res 2012;40: D1241–D1244.
22. Zhang B, Yin Y, Lai RC et al. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev 2014;23:1233–1244.
23. Lai FW, Lichty BD, Bowdish DM. Microvesicles: Ubiquitous contributors to infection and immunity. J Leukoc Biol 2015;97:237–245.
24. Pant S, Hilton H, Burczynski ME. The multifaceted exosome: Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 2012;83:1484–1494.
25. Cosset FL, Dreux M. HCV transmission by hepatic exosomes establishes a productive infection. J Hepatol 2014;60:674–675.
26. Kalamvoki M, Du T, Roizman B. Cells infected with herpes simplex virus 1 export to uninfected cells exosomes containing STING, viral mRNAs, and microRNAs. Proc Natl Acad Sci USA 2014;111:E4991–E4996.
27. Liang G, Liu G, Kitamura K et al. TGF-β suppression of HBV RNA through AID-dependent recruitment of an RNA exosome complex. PLoS Pathog 2015;11:e1004780.
28. Madison MN, Jones PH, Okeoma CM. Exosomes in human semen restrict HIV-1 transmission by vaginal cells and block intravaginal replication of LP-BM5 murine AIDS virus complex. Virology 2015;482:189–201.
29. Tan CY, Lai RC, Wong W et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther 2014;5:76.
30. Zhu X, He Z, Yuan J et al. IFITM3-containing exosome as a novel mediator for anti-viral response in dengue virus infection. Cell Microbiol 2015;17:105–118.
31. Li J, Liu K, Liu Y et al. Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity. Nat Immunol 2013; 14:793–803.
32. Yeo RW, Lai RC, Zhang B et al. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev 2013;65:336–341.
33. Zhang J, Li S, Li L et al. Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinformatics 2015;13:17–24.
34. Alexander M, Hu R, Runtsch MC et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun 2015;6:7321.
35. Cui Y, Luan J, Li H et al. Exosomes derived from mineralizing osteoblasts promote ST2 cell osteogenic differentiation by alteration of microRNA expression. FEBS Lett 2016;590: 185–192.
36. ELLS 2012;30:1556–1564.
37. Qiao C, Xu W, Zhu W et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int 2008;32:8–15.
38. Si Y, Liu S, Liu X et al. A human claudin-1derived peptide inhibits hepatitis C virus entry. Hepatology 2012;56:507–515.
39. Zhang J, Guan J, Niu X et al. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J Transl Med 2015;13:49.
40. Ti D, Hao H, Tong C et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J Transl Med 2015;13:308.
41. Tong Y, Zhu Y, Xia X et al. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol 2011;85:2793–2802.
42. Wang Y, Xu Z, Jiang J et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell 2013;25:69–80.
43. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–317.
44. Cheng M, Si Y, Niu Y et al. High-throughput profiling of alpha interferon- and interleukin28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol 2013;87:9707–9718.
45. Murakami Y, Aly HH, Tajima A et al. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009;50:453–460.
46. Wang H, Gao H, Duan S et al. Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway. Virus Res 2015;208:7–12.
47. Xu G, Yang F, Ding CL et al. MiR-221 accentuates IFN׳s anti-HCV effect by downregulating SOCS1 and SOCS3. Virology 2014; 462-463:343–350.
48. Calland N, Albecka A, Belouzard S et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 2012;55: 720–729.
49. Qian X, Xu C, Zhao P et al. Long noncoding RNA GAS5 inhibited hepatitis C virus replication by binding viral NS3 protein. Virology 2016;492:155–165.
50. Kang HS, Habib M, Chan J et al. A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. Exp Hematol 2005;33:796–803.
51. Sharma RR, Pollock K, Hubel A et al. Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices. Transfusion 2014;54:1418–1437.
52. Munir H, McGettrick HM. Mesenchymal stem cell therapy for autoimmune disease: Risks and rewards. Stem Cells Dev 2015;24:2091–2100.
53. Kang K, Ma R, Cai W et al. Exosomes secretedfromCXCR4overexpressingmesenchymal stem cells promote cardioprotection via Akt signaling pathway following myocardial infarction. Stem Cells Int 2015;2015:659890.
54. Lai RC, Arslan F, Lee MM et al. Exosome secreted by MSC reduces myocardial ischemia/ reperfusion injury. Stem Cell Res (Amst) 2010; 4:214–222.
55. Reis LA, Borges FT, Simões MJ et al. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. PLoS One 2012;7:e44092.
56. Li H, JiangJD, PengZG. MicroRNA-mediated interactions between host and hepatitis C virus. World J Gastroenterol 2016;22:1487–1496.
57. Varnholt H, Drebber U, Schulze F et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008;47:1223–1232.
58. Choi JE, Hur W, Kim JH et al. MicroRNA27a modulates HCV infection in differentiated hepatocyte-like cells from adipose tissuederived mesenchymal stem cells. PLoS One 2014;9:e91958.
59. Lee HK, Finniss S, Cazacu S et al. Mesenchymal stem cells deliver exogenous miRNAs to neural cells and induce their differentiation and glutamate transporter expression. Stem Cells Dev 2014;23:2851–2861.
60. Hoshino D, Kirkbride KC, Costello K et al. Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Reports 2013; 5:1159–1168.
61. Shimbo K, Miyaki S, Ishitobi H et al. Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem Biophys Res Commun 2014;445:381–387.